AVGO
88
-5
TMO
54
-2
EL
30
-4
DFS
62
-3
UHS
48
-2
FLR
46
-3
HSIC
47
-6
MAT
45
-2
HPE
53
-4
SCHW
42
-4
ZION
55
-5
VNO
52
-4
PG
43
-3
NVDA
47
-3
PH
60
-4
LNC
29
-4
SHW
49
-3
PHM
48
-4
FRT
43
-2
WBA
57
-6
AVGO
88
-5
TMO
54
-2
EL
30
-4
DFS
62
-3
UHS
48
-2
FLR
46
-3
HSIC
47
-6
MAT
45
-2
HPE
53
-4
SCHW
42
-4
ZION
55
-5
VNO
52
-4
PG
43
-3
NVDA
47
-3
PH
60
-4
LNC
29
-4
SHW
49
-3
PHM
48
-4
FRT
43
-2
WBA
57
-6
Financhill
Back

Sage Therapeutics Quote, Financials, Valuation and Earnings

FREE REPORT: 2025 Gold Price Outlook

Get Your Copy of "2025 Gold Forecast: A Perfect Storm for Demand" Here.
Sell
32

SAGE
Sage Therapeutics

Last Price:
5.03
Seasonality Move:
3.43%

7 Day Trial

ALL ACCESS PASS

$ 7

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here

Sage Therapeutics Price Quote

$5.03
-0.24 (-4.55%)
(Updated: December 18, 2024 at 5:55 PM ET)

Sage Therapeutics Key Stats

Sell
32
Sage Therapeutics (SAGE) is a Sell
Day range:
$5.07 - $5.48
52-week range:
$4.62 - $28.26
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.99
P/B ratio:
0.58%
Volume:
1.2M
Avg. volume:
892.2K
1-year change:
-75.67%
Market cap:
$322.4M
Revenue:
$86.5M
EPS:
$-5.57

How Much Does Sage Therapeutics Make?

Is Sage Therapeutics Growing As A Company?

  • What Is Sage Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 3.37%
  • What Is Sage Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sage Therapeutics Stock Price Performance

What Is Sage Therapeutics 52-Week High & Low?

Sage Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sage Therapeutics?

  • How Much Debt Does Sage Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Sage Therapeutics Have?
    Cash and short term investments quarterly total is $569.2M
  • What Is Sage Therapeutics’s Book Value Per Share?
    Book value per share is 9.02

Is Sage Therapeutics Cash Flow Positive?

  • What Is SAGE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$320.2M
  • What Is Sage Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $10.4M
  • What Is Sage Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $262.2M

Sage Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SAGE return on invested capital is -48.2%
  • What Is Sage Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -43.07%
  • What Is SAGE Return On Equity?
    ROE is a measure of profitability and is -48.2%

Sage Therapeutics Earnings Date & Stock Price

Sage Therapeutics Competitors

  • Who Are Sage Therapeutics's Competitors?
    Below is a list of companies who compete with Sage Therapeutics or are related in some way:
    • Biogen Inc (BIIB)
    • Johnson & Johnson (JNJ)
    • Lifecore Biomedical Inc (LFCR)
    • Organon & Co (OGN)
    • Outset Medical Inc (OM)

Sage Therapeutics Dividend Yield

Sage Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 1.32%
Revenue: 337.08% 9.37%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 17
Sell Recommendations: 0
Price Target: 9.00
Upside from Last Price: 70.78%

Major Shareholders

  • How many SAGE shares are owned by institutional investors?
    102.6M SAGE shares are owned by institutional investors
  • How many SAGE shares are owned by insiders?
    1.3M SAGE shares are owned by insiders